Entering text into the input field will update the search result below

CorMedix's (CRMD) CEO Randy Milby on Q1 2014 Results - Earnings Call Transcript

May 16, 2014 12:01 PM ETCorMedix Inc. (CRMD)
SA Transcripts profile picture
SA Transcripts

CorMedix Inc. (NASDAQ:CRMD) Q1 2014 Results Earnings Conference Call May 16, 2014 9:00 AM ET


Randy Milby - Chief Executive Officer

Steve Lefkowitz - Interim Chief Financial Officer

Dr. Tony Pfaffle - chairman



Hello ladies and gentlemen and thank you for waiting. Welcome to the CorMedix First Quarter 2014 Results Conference Call. All lines have been placed on listen only mode. And the floor will be opened for your questions and comments following the presentation. Without further ado, it’s my pleasure to turn the floor over to your host, Randy Milby. Mr. Milby, the floor is yours.

Randy Milby

Thank you. Good morning and welcome to the CorMedix first quarter 2014 conference call.

I will start by providing you with an update of our ongoing operational progress before our Interim CFO, Steve Lefkowitz addresses our financial affairs.

Before we get started, I would like to remind all the listeners that this conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements other than statements of historical facts regarding management’s expectations, beliefs, goals, plans or CorMedix prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to the variety of important factors including obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix product candidates improving marketing of Neutrolin in countries other than Germany, the risk associated with the launch of Neutrolin in Europe and other markets, the risks and uncertainties associate with CorMedix ability to manage the limited cash resources, obtaining additional financing to support CorMedix R&D and clinical activities and operations, the outcome of clinical trials for CorMedix product candidates whether they demonstrate these candidates’ safety, effectiveness and CorMedix’ ability to enter into and maintain collaborations with

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.